Literature DB >> 30061286

Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.

France Mentré1,2, Jean de Gunzburg3, Charles Burdet1,2, Sakina Sayah-Jeanne4, Thu Thuy Nguyen1, Perrine Hugon4, Frédérique Sablier-Gallis4, Nathalie Saint-Lu4, Tanguy Corbel4, Stéphanie Ferreira5, Mark Pulse6, William Weiss6, Antoine Andremont1.   

Abstract

Antibiotic disruption of the intestinal microbiota favors colonization by Clostridium difficile Using a charcoal-based adsorbent to decrease intestinal antibiotic concentrations, we studied the relationship between antibiotic concentrations in feces and the intensity of dysbiosis and quantified the link between this intensity and mortality. We administered either moxifloxacin (n = 70) or clindamycin (n = 60) to hamsters by subcutaneous injection from day 1 (D1) to D5 and challenged them with a C. difficile toxigenic strain at D3 Hamsters received various doses of a charcoal-based adsorbent, DAV131A, to modulate intestinal antibiotic concentrations. Gut dysbiosis was evaluated at D0 and D3 using diversity indices determined from 16S rRNA gene profiling. Survival was monitored until D16 We analyzed the relationship between fecal antibiotic concentrations and dysbiosis at the time of C. difficile challenge and studied their capacity to predict subsequent death of the animals. Increasing doses of DAV131A reduced fecal concentrations of both antibiotics, lowered dysbiosis, and increased survival from 0% to 100%. Mortality was related to the level of dysbiosis (P < 10-5 for the change of Shannon index in moxifloxacin-treated animals and P < 10-9 in clindamycin-treated animals). The Shannon diversity index and unweighted UniFrac distance best predicted death, with areas under the receiver operating curve (ROC) of 0.89 (95% confidence interval [CI], 0.82, 0.95) and 0.95 (0.90, 0.98), respectively. Altogether, moxifloxacin and clindamycin disrupted the diversity of the intestinal microbiota with a dependency on the DAV131A dose; mortality after C. difficile challenge was related to the intensity of dysbiosis in similar manners with the two antibiotics.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  C. difficile infection; antibiotics; dysbiosis; hamster animal model; mortality; prevention

Mesh:

Substances:

Year:  2018        PMID: 30061286      PMCID: PMC6153837          DOI: 10.1128/AAC.00925-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

Review 2.  Sequencing technologies - the next generation.

Authors:  Michael L Metzker
Journal:  Nat Rev Genet       Date:  2009-12-08       Impact factor: 53.242

3.  Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.

Authors:  Lihua Zhang; Danfeng Dong; Cen Jiang; Zhen Li; Xuefeng Wang; Yibing Peng
Journal:  Anaerobe       Date:  2015-03-26       Impact factor: 3.331

Review 4.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

5.  Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice.

Authors:  Nathalie Grall; Laurent Massias; Thu Thuy Nguyen; Sakina Sayah-Jeanne; Nicolas Ducrot; Elisabeth Chachaty; Jean de Gunzburg; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

6.  Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters.

Authors:  H E Larson; S P Borriello
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 7.  Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.

Authors:  Claudia Slimings; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2013-12-08       Impact factor: 5.790

8.  Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis.

Authors:  K H Wilson; J Silva; F R Fekety
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

9.  Gut microbiota disturbance during antibiotic therapy: a multi-omic approach.

Authors:  Ana Elena Pérez-Cobas; María José Gosalbes; Anette Friedrichs; Henrik Knecht; Alejandro Artacho; Kathleen Eismann; Wolfgang Otto; David Rojo; Rafael Bargiela; Martin von Bergen; Sven C Neulinger; Carolin Däumer; Femke-Anouska Heinsen; Amparo Latorre; Coral Barbas; Jana Seifert; Vitor Martins dos Santos; Stephan J Ott; Manuel Ferrer; Andrés Moya
Journal:  Gut       Date:  2012-12-12       Impact factor: 23.059

10.  Host-Microbiota Interactions in the Pathogenesis of Antibiotic-Associated Diseases.

Authors:  Joshua S Lichtman; Jessica A Ferreyra; Katharine M Ng; Samuel A Smits; Justin L Sonnenburg; Joshua E Elias
Journal:  Cell Rep       Date:  2016-01-28       Impact factor: 9.423

View more
  7 in total

1.  DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.

Authors:  Nathalie Saint-Lu; Charles Burdet; Frédérique Sablier-Gallis; Tanguy Corbel; Agathe Nevière; Sakina Sayah-Jeanne; Mark Pulse; William Weiss; Stéphanie Ferreira; Antoine Andremont; France Mentré; Jean de Gunzburg
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Impact of Antibiotic Gut Exposure on the Temporal Changes in Microbiome Diversity.

Authors:  Charles Burdet; Thu Thuy Nguyen; Xavier Duval; Stéphanie Ferreira; Antoine Andremont; Jérémie Guedj; France Mentré
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study.

Authors:  Catherine A Hogan; Matthew M Hitchcock; Spencer Frost; Kristopher Kapphahn; Marisa Holubar; Lucy S Tompkins; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2022-05-25       Impact factor: 11.677

4.  Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbation.

Authors:  Jinju Guk; Antoine Bridier-Nahmias; Mélanie Magnan; Nathalie Grall; Xavier Duval; Olivier Clermont; Etienne Ruppé; Camille d'Humières; Olivier Tenaillon; Erick Denamur; France Mentré; Jérémie Guedj; Charles Burdet
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-18

5.  Gut microbiota features associated with Clostridioides difficile colonization in puppies.

Authors:  Alexander S F Berry; Brendan J Kelly; Denise Barnhart; Donna J Kelly; Daniel P Beiting; Robert N Baldassano; Laurel E Redding
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

6.  An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.

Authors:  Maria J G T Vehreschild; Annie Ducher; Thomas Louie; Oliver A Cornely; Celine Feger; Aaron Dane; Marina Varastet; Fabien Vitry; Jean de Gunzburg; Antoine Andremont; France Mentré; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

7.  Cryptosporidium parvum Infection Depletes Butyrate Producer Bacteria in Goat Kid Microbiome.

Authors:  Mohamed Mammeri; Dasiel Alvarez Obregón; Aurélie Chevillot; Bruno Polack; Christine Julien; Thomas Pollet; Alejandro Cabezas-Cruz; Karim Tarik Adjou
Journal:  Front Microbiol       Date:  2020-10-16       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.